ITMCTR2000003420
Not yet recruiting
Phase 1
Research on the mechanism of multimodal imaging effect of Taijiquan movement on the decline of subjective cognitive function based on default network
Fujian University of Traditional Chinese Medicine0 sitesTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Fujian University of Traditional Chinese Medicine
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients who meet the diagnostic criteria of SCD;
- •2\. Patients aged 60\-75 years;
- •3\. There was no objective clinical damage of MCI in patients with score of Montreal cognitive function assessment scale \>\= 26;
- •4\. Patients who have not been engaged in regular exercise in the last six months;
- •5\. Patients with right handedness;
- •6\. Patients with informed consent and voluntary participation.
Exclusion Criteria
- •1\. Hypertension patients whose blood pressure cannot be controlled;
- •2\. Patients with history of alcohol and drug abuse;
- •3\. Patients with cognitive decline caused by other reasons;
- •4\. Patients with sports contraindications and low education level who can not cooperate with the test;
- •5\. Patients with contraindications of MRI and taking drugs affecting brain imaging;
- •6\. Patients who are participating in other study trials that affect the results of this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
inking multimodal network imaging and cognitive functioning in glioma patientsNL-OMON55895Vrije Universiteit Medisch Centrum275
Recruiting
Not Applicable
Rein 3D PRINT MECHANICSKidney CancerNCT06525831University Hospital, Bordeaux50
Terminated
Not Applicable
Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent GlioblastomaGlioblastomaNCT02841332University Hospital, Toulouse6
Active, not recruiting
Phase 1
Phase 2a open label study of Fovista¿ (anti-PDGF agent) administered in combination with anti-VEGF therapy in subjects previously treated or treatment-naive.Subfoveal choroidal neovascularization secondary to Age-Related Macular Degeneration (AMD)MedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.1Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2015-000519-42-ITIVERIC bio, Inc.32
Active, not recruiting
Phase 1
Role of imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month study of Fovista® (anti-PDGF therapy) administered in combination with anti-VEGF therapySubfoveal choroidal neovascularization secondary to Age-Related Macular Degeneration (AMD)MedDRA version: 18.0 Level: PT Classification code 10071129 Term: Neovascular age-related macular degeneration System Organ Class: 10015919 - Eye disordersMedDRA version: 18.0 Level: LLT Classification code 10067791 Term: Wet macular degeneration System Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2015-000519-42-FROPHTHOTECH CORPORATIO32